131 related articles for article (PubMed ID: 38738701)
21. Interaction of marine toxin dolastatin 10 with porcine brain tubulin: competitive inhibition of rhizoxin and phomopsin A binding.
Li Y; Kobayashi H; Hashimoto Y; Shirai R; Hirata A; Hayashi K; Hamada Y; Shioiri T; Iwasaki S
Chem Biol Interact; 1994 Dec; 93(3):175-83. PubMed ID: 7923438
[TBL] [Abstract][Full Text] [Related]
22. Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications.
Pettit GR; Srirangam JK; Barkoczy J; Williams MD; Durkin KP; Boyd MR; Bai R; Hamel E; Schmidt JM; Chapuis JC
Anticancer Drug Des; 1995 Oct; 10(7):529-44. PubMed ID: 7495477
[TBL] [Abstract][Full Text] [Related]
23. Biosynthesis of Dolastatin 10 in Marine Cyanobacteria, a Prototype for Multiple Approved Cancer Drugs.
Kallifidas D; Dhakal D; Chen M; Chen QY; Kokkaliari S; Colon Rosa NA; Ratnayake R; Bruner SD; Paul VJ; Ding Y; Luesch H
Org Lett; 2024 Feb; 26(7):1321-1325. PubMed ID: 38330916
[TBL] [Abstract][Full Text] [Related]
24. Polymer-DNA assembled nanoflower for targeted delivery of dolastatin-derived microtubule inhibitors.
Wu T; Shi Y; Yang T; Zhao P; Yang Z; Yang B
RSC Adv; 2024 Mar; 14(14):9602-9608. PubMed ID: 38516154
[TBL] [Abstract][Full Text] [Related]
25. The spongistatins, potently cytotoxic inhibitors of tubulin polymerization, bind in a distinct region of the vinca domain.
Bai R; Taylor GF; Cichacz ZA; Herald CL; Kepler JA; Pettit GR; Hamel E
Biochemistry; 1995 Aug; 34(30):9714-21. PubMed ID: 7626642
[TBL] [Abstract][Full Text] [Related]
26. Discovery of Dolastatinol: A Synthetic Analog of Dolastatin 10 and Low Nanomolar Inhibitor of Tubulin Polymerization.
Gutman H; Bazylevich A; Prasad C; Dorfman O; Hesin A; Marks V; Patsenker L; Gellerman G
ACS Med Chem Lett; 2021 Oct; 12(10):1596-1604. PubMed ID: 34676042
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial of dolastatin-10 in patients with advanced breast cancer.
Perez EA; Hillman DW; Fishkin PA; Krook JE; Tan WW; Kuriakose PA; Alberts SR; Dakhil SR
Invest New Drugs; 2005 Jun; 23(3):257-61. PubMed ID: 15868383
[TBL] [Abstract][Full Text] [Related]
28. Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay.
Aherne GW; Hardcastle A; Valenti M; Bryant A; Rogers P; Pettit GR; Srirangam JK; Kelland LR
Cancer Chemother Pharmacol; 1996; 38(3):225-32. PubMed ID: 8646796
[TBL] [Abstract][Full Text] [Related]
29. Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: induction of apoptosis and bcl-2 modification.
Kalemkerian GP; Ou X; Adil MR; Rosati R; Khoulani MM; Madan SK; Pettit GR
Cancer Chemother Pharmacol; 1999; 43(6):507-15. PubMed ID: 10321512
[TBL] [Abstract][Full Text] [Related]
30. Direct photoaffinity labeling by dolastatin 10 of the amino-terminal peptide of beta-tubulin containing cysteine 12.
Bai R; Covell DG; Taylor GF; Kepler JA; Copeland TD; Nguyen NY; Pettit GR; Hamel E
J Biol Chem; 2004 Jul; 279(29):30731-40. PubMed ID: 15123603
[TBL] [Abstract][Full Text] [Related]
31. Diazonamide A and a synthetic structural analog: disruptive effects on mitosis and cellular microtubules and analysis of their interactions with tubulin.
Cruz-Monserrate Z; Vervoort HC; Bai R; Newman DJ; Howell SB; Los G; Mullaney JT; Williams MD; Pettit GR; Fenical W; Hamel E
Mol Pharmacol; 2003 Jun; 63(6):1273-80. PubMed ID: 12761336
[TBL] [Abstract][Full Text] [Related]
32. Ancient DNA analysis identifies marine mollusc shells as new metagenomic archives of the past.
Der Sarkissian C; Pichereau V; Dupont C; Ilsøe PC; Perrigault M; Butler P; Chauvaud L; Eiríksson J; Scourse J; Paillard C; Orlando L
Mol Ecol Resour; 2017 Sep; 17(5):835-853. PubMed ID: 28394451
[TBL] [Abstract][Full Text] [Related]
33. Role of P-glycoprotein in dolastatin 10 resistance.
Toppmeyer DL; Slapak CA; Croop J; Kufe DW
Biochem Pharmacol; 1994 Aug; 48(3):609-12. PubMed ID: 7915113
[TBL] [Abstract][Full Text] [Related]
34. Sustained intracellular retention of dolastatin 10 causes its potent antimitotic activity.
Verdier-Pinard P; Kepler JA; Pettit GR; Hamel E
Mol Pharmacol; 2000 Jan; 57(1):180-7. PubMed ID: 10617693
[TBL] [Abstract][Full Text] [Related]
35. Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1.
Bai R; Durso NA; Sackett DL; Hamel E
Biochemistry; 1999 Oct; 38(43):14302-10. PubMed ID: 10572005
[TBL] [Abstract][Full Text] [Related]
36. Marine Antitumor Peptide Dolastatin 10: Biological Activity, Structural Modification and Synthetic Chemistry.
Gao G; Wang Y; Hua H; Li D; Tang C
Mar Drugs; 2021 Jun; 19(7):. PubMed ID: 34202685
[TBL] [Abstract][Full Text] [Related]
37. Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors.
Madden T; Tran HT; Beck D; Huie R; Newman RA; Pusztai L; Wright JJ; Abbruzzese JL
Clin Cancer Res; 2000 Apr; 6(4):1293-301. PubMed ID: 10778954
[TBL] [Abstract][Full Text] [Related]
38. Effects of the antimitotic natural product dolastatin 10, and related peptides, on the human malarial parasite Plasmodium falciparum.
Fennell BJ; Carolan S; Pettit GR; Bell A
J Antimicrob Chemother; 2003 Apr; 51(4):833-41. PubMed ID: 12654761
[TBL] [Abstract][Full Text] [Related]
39. Dolastatin 15 induces apoptosis and BCL-2 phosphorylation in small cell lung cancer cell lines.
Ali MA; Rosati R; Pettit GR; Kalemkerian GP
Anticancer Res; 1998; 18(2A):1021-6. PubMed ID: 9615758
[TBL] [Abstract][Full Text] [Related]
40. Conformational behaviour of the antineoplastic peptide dolastatin-10 and of two mutated derivatives.
Fantucci P; Marino T; Russo N; Villa AM
J Comput Aided Mol Des; 1995 Oct; 9(5):425-38. PubMed ID: 8594160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
